Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Tejeshwar Jain

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1886-685X; OpenAlex author ID A5084358039. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 10

  1. Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC. Co-author DOI 10.1016/j.cytogfr.2026.01.009↗
  2. Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma-Past, Present, and Future. First author DOI 10.3390/cancers18172754↗
  3. Peritoneal Cell-Free DNA: A Novel Biomarker for Recurrence in Pancreatic Cancer. First author DOI 10.1245/s10434-023-13947-w↗
  4. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
  5. An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. Co-author DOI 10.1007/s11605-020-04681-9↗
  6. Neoadjuvant therapy alters the biliary microbiome in PDAC. Co-author DOI 10.1016/j.amjsurg.2020.12.050↗
  7. The war against pancreatic cancer in 2020 - advances on all fronts. Co-author DOI 10.1038/s41575-020-00410-4↗
  8. Hsp70 modulates immune response in pancreatic cancer through dendritic cells. Co-author DOI 10.1080/2162402x.2021.1976952↗
  9. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. First author DOI 10.3390/ijms222413408↗
  10. Symphony in chaos: Immune orchestra during pancreatic cancer progression. First author DOI 10.1016/j.ebiom.2020.102787↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vikas Dudeja · 8 shared papers, 2020–2023 · strength 1.57
  2. Utpreksha Vaish · 4 shared papers, 2021–2026 · strength 0.71
  3. Srikanth Iyer · 3 shared papers, 2021–2026 · strength 0.52
  4. Vrishketan Sethi · 4 shared papers, 2020–2022 · strength 0.51
  5. Prateek Sharma MD · 4 shared papers, 2020–2022 · strength 0.51
  6. Naomi H. Fei · 1 shared paper, 2026 · strength 0.43
  7. Andy Tran · 1 shared paper, 2026 · strength 0.43
  8. Vikas Dudeja · 1 shared paper, 2026 · strength 0.43
  9. Bhuwan Giri · 3 shared papers, 2021–2022 · strength 0.35
  10. Angela Sickels · 1 shared paper, 2023 · strength 0.31
  11. Suresh Sulekha Dhanisha · 1 shared paper, 2026 · strength 0.29
  12. Nipun B. Merchant · 2 shared papers, 2021–2022 · strength 0.24
  13. Sundaram Ramakrishnan · 2 shared papers, 2021 · strength 0.22
  14. Harrys K.C. Jacob · 2 shared papers, 2021 · strength 0.22
  15. Anthony R. Ferrantella · 2 shared papers, 2021 · strength 0.22
  16. Ashok Kumar Saluja · 2 shared papers, 2021 · strength 0.22
  17. John Bart Rose · 1 shared paper, 2022 · strength 0.13
  18. Sushanth Reddy · 1 shared paper, 2022 · strength 0.13
  19. Suresh T. Chari · 1 shared paper, 2022 · strength 0.13
  20. Jashodeep Datta · 1 shared paper, 2022 · strength 0.13
  21. Sulagna Banerjee · 1 shared paper, 2021 · strength 0.11
  22. Shrey Modi · 1 shared paper, 2021 · strength 0.11
  23. Zoe X. Malchiodi · 1 shared paper, 2021 · strength 0.10
  24. Bharti Garg · 1 shared paper, 2021 · strength 0.10
  25. Siddharth Mehra · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.